Newcomers Club
For newcomers and current members alike, this is the place to get answers for more entry-level... View more
Organizer:
- Organized by
-
-
Reply To: Low Cholesterol
-
This is easy work for flush niacin (especially with equimolar N-acetyl-L-glutamine to boot) per https://HOM3OSTASIS.com/Protocol :
“This meta-analysis involved 2,110 patients with T2DM from 8 RCTs across a wide range of patients’ characteristics. The results of this study suggested that niacin supplementation significantly reduced TC, TG, & LDL, and increased the level of HDL.”
Effectiveness of niacin supplementation for patients with type 2 diabetes
A meta-analysis of randomized controlled trials
“Niacin use significantly increased HDL-C by 29% and 29% and decreased triglycerides by 23% and 28% and LDL-C by 8% and 9%, respectively, in participants with and without diabetes.”
Effect of Niacin on Lipid and Lipoprotein Levels and Glycemic Control in Patients With Diabetes and Peripheral Arterial Disease
The ADMIT Study: A Randomized Trial
https://jamanetwork.com/journals/jama/fullarticle/193064
“niacin therapy had typical effects on routine clinical lipids (HDL-C + 16%, q < 0.01; LDL-C − 20%, q < 0.01; and triglyceride − 15%, q = 0.1)”
Effect of niacin monotherapy on high density lipoprotein composition and function
https://lipidworld.biomedcentral.com/articles/10.1186/s12944-020-01350-3
“niacin retains an FDA-approved indication as monotherapy for treating dyslipidemia, a main risk factor for cardiovascular events and myocardial infarction”
“Stratified meta-analysis showed an association of niacin monotherapy with reduction of some cardiovascular events among patients WITHOUT statins (acute coronary syndrome: relative risk, 0.68; 95% CI, 0.58-0.96; stroke: 0.69; 95% CI, 0.59-0.94; revascularization: 0.51; 95% CI, 0.37-0.72). These results were mainly derived from 2 trials conducted in the 1970s and 1980s”
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes
A Systematic Review and Meta-analysis
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2730481
“Our study concludes that lipid-modifying dosages of niacin can be safely used in patients with diabetes and that niacin should be used for patients with diabetes to sufficiently correct hypertriglyceridemia or low HDL-C levels.”
Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
“concluded from many clinical trials using statins, lowering LDL-C alone is no longer regarded to be sufficient to treat CVD
comprehensive lipid management, in which raising HDL is an important target, a new standard. Niacin is UNSURPASSED in raising HDL”
Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein